Treatment of Multifocal Lung Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-06

Study Completion Date

2025-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

NCT02705404

Lung Neoplasms Carcinoma Non-small-cell Lung

TERMINATED

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

NCT02470819

Metastatic Breast Cancer Breast Tumor Advanced Gynecologic Cancer

WITHDRAWN NA

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723

Malignant Pleural Mesotheliomas NOS Esophageal Cancers NOS Lung Cancer NOS +2 more

RECRUITING

Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma

NCT00568906

Carcinoma, Giant Cell Carcinoma, Non-Small-Cell Lung Lung Cancer

TERMINATED

Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

NCT02566421

Metastatic Neoplasm Recurrent Neoplasm Recurrent Non-Small Cell Lung Carcinoma +4 more

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung bronchoalveolar carcinoma (BAC) or adenocarcinoma in situ (AIS) continues to represent a poorly understood clinical entity. A frequent clinical dilemma in lung cancer care is the management of a documented or suspected invasive adenocarcinoma in the setting of multifocal ground glass opacity (GGO) consistent with multifocal AIS. These patients are typically classified as stage IV disease, and treated with palliative chemotherapy. No existing pathologic or molecular test is currently capable of making the distinction between independent primary versus metastatic tumors, a distinction for which substantial treatment impact exists. Many treating physicians suspect that outcomes for this specific patient subgroup are better than norms for stage IV disease, as such patients are frequently node-negative and without distant metastases despite multiple lesions present. To address this issue, we will evaluate a multimodality treatment protocol using aggressive local and targeted systemic therapy for multifocal lung adenocarcinoma, incorporating information from tumor genome sequencing for individualized treatment planning. The results will have significant impact in advancing the biologic understanding and treatment approach for lung adenocarcinoma in the setting of multifocal AIS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms Carcinoma Non-small-cell Lung Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multifocal Lung Adenocarcinoma

Group Type OTHER

Multifocal Lung Adenocarcinoma

Intervention Type GENETIC

Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multifocal Lung Adenocarcinoma

Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be \> 18 years of age
* Two or more GGO's or solid lesions suspicious for multifocal disease.
* Clinical diagnosis of N0
* No evidence of distant metastases
* No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC).
* No other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin.
* PFT's that show patient is capable of tolerating a lung resection.
* Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study.
* Patient must be able to understand and willing to sign an IRB-approved informed consent document.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No